Arcutis FDA Accepts ZORYVE sNDA for Infant Dermatitis
WESTLAKE VILLAGE, Calif., July 8, 2026 Arcutis Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WESTLAKE VILLAGE, Calif., July 8, 2026 Arcutis Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted...
WESTLAKE VILLAGE, Calif., June 29, 2026 Arcutis Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Westlake Village, California, United States – March 10, 2026 Arcutis Biotherapeutics has announced that the U.S. Food and Drug...
